Drug Profile
Research programme: respiratory syncytial virus therapeutics - MicroDose Therapeutx
Alternative Names: RSV therapeutics - MicroDose TherapeutxLatest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator ViroPharma
- Developer MicroDose Therapeutx
- Class Small molecules
- Mechanism of Action Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 20 Apr 2011 No development reported for Respiratory syncytial virus infections in USA (Inhalation)
- 29 Nov 2009 Early research in Respiratory syncytial virus infections in USA (Inhalation)